Delivery Order SPE2DB22D1017-SPE2DB25FG9EE
- Not listed
- The Defense Logistics Agency awarded a $2,416.05 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, with completion scheduled for July 29, 2025. This non-competitive delivery order was placed against AmerisourceBergen's broader pharmaceutical supply contract vehicle and will be performed at the contractor's facility in Conshohocken, Pennsylvania. HUMIRA is a widely-used biologic medication for treating autoimmune...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,265.90 delivery order on July 18, 2025, for HUMIRA (CF) Pen 40 mg/0.4 mls, with completion scheduled for July 21, 2025. This competitive award, issued under firm fixed pricing with no set-aside designation, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical product...
- The Defense Logistics Agency awarded a $1,888.25 delivery order contract to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, with an ultimate completion date of August 5, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves...
- The Defense Logistics Agency awarded a delivery order valued at $9,166.50 to AmerisourceBergen Drug Corp for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product used in the treatment of autoimmune conditions. This contract type represents a firm fixed price delivery order with no set-aside designation, indicating the award was made through open competition. The order was executed on July 21, 2025, with an ultimate completion date of July 22, 2025, and will be performed at...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $10,212.51 delivery order on July 23, 2025, for HUMIRA Pen 40 mg/0.8 mL, a pharmaceutical product for treating autoimmune conditions. This is a firm fixed-price contract with no set-aside designation, competitively awarded to the prime contractor's corporate office located in Conshohocken, Pennsylvania, with ultimate performance completion scheduled for July 24, 2025. The contract represents a routine pharmaceutical procurement...
- The Defense Logistics Agency awarded a delivery order valued at $5,543.70 to AmerisourceBergen Drug Corp for the supply of Humira Pen 40 mg/0.8 mls, a pharmaceutical product used to treat inflammatory conditions. This competitively awarded, firm fixed-price contract was issued on July 22, 2025, with an ultimate completion date of July 23, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,510.62 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 80 mg/0.8 mL on August 1, 2025, with an ultimate completion date of August 4, 2025. This firm fixed-price delivery order was issued without a set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. HUMIRA is a widely-used pharmaceutical for treating various autoimmune conditions and is a critical medical supply required...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $14,041.38 to AmerisourceBergen Drug Corp for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product used in the treatment of autoimmune conditions. This firm fixed-price delivery order was awarded on July 21, 2025, with an ultimate completion date of July 22, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract utilized competitive procurement procedures with no...
- The Defense Logistics Agency awarded a $21,582.58 delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL, a specialty pharmaceutical product used in the treatment of autoimmune conditions. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 8, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. No set-aside designation was applied to this award. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL, a biologic medication used to treat autoimmune conditions. This firm fixed-price delivery order, valued at $1,860.59, was competitively awarded with no set-aside designation and is scheduled for completion by August 5, 2025. AmerisourceBergen Drug Corp will perform the work from its corporate office location in Conshohocken, Pennsylvania. This...
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB25FG9EEDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of HUMIRA(CF) Pen 80 mg/0.8 mls, a pharmaceutical product used in the treatment of autoimmune conditions. This firm fixed price delivery order, valued at $1,453.31, represents a single transaction under AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. The award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's demonstrated capability to meet federal medical procurement standards. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters and primary distribution operations. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle. The parent IDC enables AmerisourceBergen to supply an extensive range of pharmaceutical products and medical supplies to support military healthcare systems worldwide, including medications, vaccines, and specialized medical devices across multiple therapeutic areas. The contract with an ultimate completion date of August 8, 2025, demonstrates the DLA's reliance on AmerisourceBergen as a critical vendor within its Medical Supply Chain supporting Defense Health Agency operations and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.5k | 8/7/25 |